Rezolute, Inc.
NASDAQ:RZLTBiotechnology
+$0.30 today
- Market cap
- $411.10M
- Beta
- 0.65
- P/E (TTM)
- -6.5
- EPS (TTM)
- -$0.78
Volume 2.93M
Average 2.03M
Returns on capital
Rezolute, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-45.9%
avg -186.0%
ROIC
-48.7%
avg 691.4%
ROA
-42.4%
avg -206.1%
Analysis
ROA is currently the strongest return metric at -42.4% versus its period average of -206.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Nevan Charles Elam | Founder, Chief Executive Officer & Acting Chairman of the Board | USD 1.13M | 59 | — | — |
Brian Kenneth Roberts | Chief Medical Officer | USD 789.22K | 51 | 293.85K | 0.31% |
Daron G. Evans | Chief Financial & Business Officer | USD 738.05K | 52 | — | — |
Sunil Karnawat | Chief Commercial Officer | USD 678.8K | 59 | — | — |
Gopal Saha MBBS | Senior Vice President of Global Clinical Development | — | — | — | — |
Raj Agrawal | Vice President & Head of Ophthalmological Clinical Development | — | — | — | — |
Chris Milks | Vice President & Head of Finance | — | — | — | — |
Erin O'Boyle | Senior Vice President & Head of Clinical Operations | — | — | — | — |
Melissa Quinn | Senior Director of People and Culture | — | — | — | — |
Robyn Sweinhart | Vice President & Head of Quality | — | — | — | — |
Susan Stewart | Chief Regulatory Officer | — | 65 | — | — |
Davelyn Eaves Hood | Director and Head of Scientific & Patient Affairs | — | — | — | — |
Michael Covarrubias | Senior Vice President & Head of Program & Portfolio Management | — | — | — | — |
Michael R. Deperro | Senior VP & Head of Operations | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jul 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
10
$288,871.76
Sells
0
$0.00
Net Transaction Value
+$288,871.76
Net buying
Most Active
Evans Daron
5 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Mar 30, 26Mar 30, 2026 | Evans Daron Direct | Buy | $28.5K$28,500.00 |
| Dec 16, 25Dec 16, 2025 | Hogenhuis Wladimir Direct | Buy | $9.5K$9,548.50 |
| Dec 16, 25Dec 16, 2025 | ROBERTS BRIAN KENNETH Direct | Buy | $47.6K$47,600.00 |
| Dec 15, 25Dec 15, 2025 | Evans Daron Direct | Buy | $70.6K$70,640.00 |
| Dec 15, 25Dec 15, 2025 | Evans Daron Indirect | Buy | $4.5K$4,462.50 |
| Dec 15, 25Dec 15, 2025 | Evans Daron Indirect | Buy | $4.5K$4,475.00 |
| Dec 15, 25Dec 15, 2025 | Elam Nevan C Direct | Buy | $50.9K$50,880.00 |
| Dec 15, 25Dec 15, 2025 | Karnawat Sunil Ratilal Direct | Buy | $160$160.00 |
| Dec 15, 25Dec 15, 2025 | Karnawat Sunil Ratilal Direct | Buy | $19.4K$19,438.80 |
| Dec 9, 25Dec 9, 2025 | Evans Daron Direct | Buy | $53.2K$53,166.96 |
Summary
Insiders reported 10 buys worth $288,871.76 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $288,871.76. Evans Daron was the most active insider with 5 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A2 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Rezolute, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about RZLT's management, answered from reported figures.
Who manages RZLT?
Rezolute, Inc. (RZLT) lists 14 active executives. The top listed executive is Brian Kenneth Roberts, Chief Medical Officer.
Are RZLT insiders buying or selling?
Recent insider activity shows net buying of $44.21M.
Continue the stock analysis
Jump to another research area for this company.